Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors.

ABSTRACT:

Purpose

We evaluated longitudinal tracking of BRAF V600E in circulating cell-free DNA (cfDNA) as a marker of treatment response to BRAF inhibitor (BRAFi) combination therapies in non-melanoma solid tumors included in the Copenhagen Prospective Personalized Oncology (CoPPO) program.

Experimental design

Patients with BRAF V600E-mutated tumors were treated with combination therapies including BRAFi. Quantification of mutant cfDNA from plasma was determined and correlated to clinical outcomes. Exome sequencing was performed to identify possible resistance mutations.

Results

Twenty-three patients had BRAF-mutated tumors out of 455 patients included in CoPPO and 17 started BRAFi combination (EGFRi/MEKi) therapy. Tumor responses were achieved in 8 out of 16 evaluable patient

SUBMITTER: Ahlborn LB 

PROVIDER: S-EPMC6135692 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature